What the Evidence Shows About Tysabri and PML

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Risk Awareness

If you or a loved one is taking Tysabri and concerned about PML, understanding the medical evidence is essential. Decades of pharmacovigilance and clinical research have established a clear link between Tysabri and PML, along with identifiable risk factors. This page provides an objective summary of what the science currently shows about symptoms, diagnosis, and monitoring.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative integrates clinical, pharmacological, and risk-related evidence to inform patients and their legal representatives. Clinical Presentation and Diagnosis of PML PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised individuals, and it usually leads to death or severe disability ( https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 ). The condition presents with progressive neurological deficits, including cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because the disease can advance rapidly.

Pharmacology and Reported Adverse Effects of Tysabri

Tysabri is a monoclonal antibody that binds to alpha-4 integrins, preventing immune cell migration into the central nervous system. While this mechanism reduces inflammatory activity in multiple sclerosis, it also impairs immune surveillance against JC virus, creating a permissive environment for PML development. The FDA Adverse Event Reporting System (FAERS) data show that the most frequently reported adverse events associated with Tysabri include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), and memory impairment (7,895 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports reflect the broad spectrum of neurological symptoms that may overlap with PML presentation, complicating early detection.

Mechanistic Pathways Linking Tysabri to PML

The link between Tysabri and PML is well-established. The drug's boxed warning states that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. In clinical trials, PML occurred in three patients who received Tysabri: two among 1,869 multiple sclerosis patients treated for a median of 120 weeks (both also received interferon beta-1a), and one among 1,043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the importance of risk stratification and monitoring.

Adequacy of Warnings and Legal Considerations

The prescribing information for Tysabri includes a boxed warning that clearly states the risk of PML and the need for monitoring. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and prescribers fully understand the magnitude of risk, especially in those with multiple risk factors. The adequacy of communication regarding the interaction between duration of therapy and anti-JCV antibody status is a key consideration for affected individuals. For patients who develop PML after Tysabri treatment, legal considerations may include whether the manufacturer provided sufficient warnings about the risk and whether the patient was adequately monitored. The boxed warning and TOUCH program represent regulatory efforts to mitigate risk, but individual cases may involve failure to adhere to monitoring protocols or to promptly withhold treatment when symptoms appear. Patients and their families should document the timeline of treatment, any symptoms that arose, and the response of healthcare providers. Legal counsel experienced in pharmaceutical injury cases can evaluate whether the warnings were adequate and whether the patient's specific risk factors were properly assessed.

Timeline Between Exposure and Documented Harm

The onset of PML can occur after varying durations of Tysabri therapy. In clinical trials, one case occurred after eight doses in a Crohn's disease patient, while two multiple sclerosis patients developed PML after a median of 120 weeks of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk increases with longer treatment duration, particularly beyond two years. Patients who have received prior immunosuppressants are also at elevated risk. Early symptoms of PML may be subtle and can mimic common adverse effects of Tysabri, such as fatigue, headache, or gait disturbance, which are frequently reported in FAERS data (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). This overlap underscores the need for heightened vigilance and prompt diagnostic evaluation when new neurological symptoms emerge.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus, as indicated by its boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What symptoms should prompt immediate medical evaluation in Tysabri patients?

New or worsening neurological symptoms such as cognitive impairment, motor weakness, gait disturbance, or visual changes may indicate PML. These symptoms can overlap with common Tysabri side effects like fatigue and headache (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

How is PML diagnosed?

Diagnosis involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.